RE: Kymab was sold for 1.45 billion to Sanofi in January11 Jun 2021 12:29
A Kymab 1.45 billion style deal would be a multiple of ten based on our current share price, taking the SAR share price to over 47p. However, I would suggest that we have much more value in our IP pipeline with SDC 1801, 1802, SRA737 etc. Therefore our intrinsic value should be much greater to a major pharma. 47p for starters maybe and then a bidding war!